Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07057765

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Sponsor: Ain Shams University

View on ClinicalTrials.gov

Summary

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Official title: Predictive Value of CRP, Albumin, CAR, and mGPS in DLBCL: A Prospective Cohort Study on Treatment Outcomes and Toxicity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

OBSERVATIONAL

Enrollment

40

Start Date

2025-05-05

Completion Date

2026-08

Last Updated

2025-07-10

Healthy Volunteers

No

Interventions

DRUG

Observational Assessment of Standard R-CHOP Treatment

Patients will receive R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as part of routine clinical care. The study does not assign or modify treatment. Data will be collected to assess the association between inflammatory markers and clinical outcomes.

Locations (1)

Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University

Cairo, Cairo Governorate, Egypt